263 related articles for article (PubMed ID: 25200248)
1. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
2. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
3. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
4. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
5. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
6. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
9. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
11. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
14. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia.
Yamasaki H; Era T; Asou N; Sanada I; Matutes E; Yamaguchi K; Takatsuki K
Leukemia; 1995 Jul; 9(7):1147-53. PubMed ID: 7630188
[TBL] [Abstract][Full Text] [Related]
15. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
16. FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.
de Oliveira FM; Miguel CE; Lucena-Araujo AR; de Lima AS; Falcão RP; Rego EM
Med Oncol; 2013 Mar; 30(1):483. PubMed ID: 23389918
[TBL] [Abstract][Full Text] [Related]
17. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
[TBL] [Abstract][Full Text] [Related]
18. Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
20. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
